{"commentary":{"count":352,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":164,"youtube":102,"podcast":79,"x_video":7},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03924895\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT03924895","nct_id":"NCT03924895","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03924895. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Participants receive 3 preoperative cycles of pembrolizumab, followed by standard of care surgery, followed by 14 cycles of postoperative pembrolizumab. Each cycle is 21 days.","label":"Arm A: Pembrolizumab + Surgery","type":"EXPERIMENTAL"},{"description":"Participants receive standard of care surgery alone.","label":"Arm B: Surgery alone","type":"ACTIVE_COMPARATOR"},{"description":"Participants receive 3 preoperative cycles of enfortumab vedotin + pembrolizumab, followed by standard of care surgery, followed by 6 cycles of postoperative enfortumab vedotin + pembrolizumab, followed by 8 cycles of pembrolizumab alone. Each cycle is 21 days.","label":"Arm C: Enfortumab Vedotin + Pembrolizumab + Surgery","type":"EXPERIMENTAL"}],"collaborators":["Seagen Inc.","Astellas Pharma Global Development, Inc."],"completion_date":{"date":"2027-12-15","type":"ESTIMATED"},"conditions":["Urinary Bladder Cancer, Muscle-invasive"],"enrollment":{"count":595,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Pembrolizumab","type":"DRUG"},{"name":"Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])","type":"PROCEDURE"},{"name":"Enfortumab Vedotin","type":"DRUG"}],"last_update":"2026-06-30","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Randomized Phase 3 Study Evaluating Cystectomy With Perioperative Pembrolizumab and Cystectomy With Perioperative Enfortumab Vedotin and Pembrolizumab Versus Cystectomy Alone in Participants Who Are Cisplatin-Ineligible or Decline Cisplatin With Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-06-06","type":"ACTUAL"},"primary_outcomes":[{"measure":"Event-Free Survival (EFS) Between Arm C: Enfortumab Vedotin + Pembrolizumab + Surgery and Arm B: Surgery Alone","timeFrame":"Up to approximately 53 months"}],"references":[{"citation":"Vulsteke C, Adra N, Danchaivijitr P, Sabadash M, Rodriguez-Vida A, Zhang Z, Atduev V, Goger YE, Rausch S, Kang SH, Loriot Y, Bedke J, Galsky MD, O'Donnell PH, von Amsberg G, Alimohamed N, Sulimka G, Gupta S, Paramonov V, Nakane K, Mihm M, Meng C, Huang CD, Ramamurthy C, Homet Moreno B, Ullen A; KEYNOTE-905/EV-303 Investigators. Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. N Engl J Med. 2026 Apr 2;394(13):1257-1269. doi: 10.1056/NEJMoa2511674. Epub 2026 Feb 18.","pmid":"41707170","type":"DERIVED"},{"citation":"Galsky MD, Hoimes CJ, Necchi A, Shore N, Witjes JA, Steinberg G, Bedke J, Nishiyama H, Fang X, Kataria R, Sbar E, Jia X, Siefker-Radtke A. Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. Future Oncol. 2021 Aug;17(24):3137-3150. doi: 10.2217/fon-2021-0273. Epub 2021 May 19.","pmid":"34008425","type":"DERIVED"}],"start_date":{"date":"2019-07-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)","url":"https://clinicaltrials.gov/study/NCT03924895"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03924895"}